![Hui Ju Chan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hui Ju Chan
Direttore/Membro del Consiglio presso
PHARMADAX INC.
Profilo
Hui Ju Chan currently works at PharmaDax (Guangzhou), Inc., as Chairman, Empax Pharma (Foshan) Inc., as Chairman, PharmaDax Inc., as Director, PharmaDax USA, Inc., as Director, Sandex Group Ltd., as Director, Fortune Tower Group Corp., as Director, and Shengqun Pharmaceutical Co., Ltd., as Director.
Ms. Chan received her undergraduate degree from National Taipei University of Technology and Masters Business Admin degree from Soochow University.
Posizioni attive di Hui Ju Chan
| Società | Posizione | Inizio |
|---|---|---|
| PHARMADAX INC. | Direttore/Membro del Consiglio | - |
PharmaDax (Guangzhou), Inc. | Presidente | - |
PharmaDax USA, Inc.
 PharmaDax USA, Inc. Pharmaceuticals: MajorHealth Technology The company is located in the US. Part of PharmaDax Inc., PharmaDax USA, Inc. is an American pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty modified-release oral solid dosage drugs. The company focuses on complex sustained-release formulations primarily in central nervous system (CNS) and cardiovascular system (CVS) therapeutic areas. PharmaDax operates two GMP-compliant manufacturing facilities with a combined tablet production capacity of 600 million units annually, expandable to 1.5 billion, and employs around 230 team members across five countries. Its proprietary technology platforms include non-erosive adjustable drug delivery systems, modified-release orally disintegrating tablets, sustained-release gastro-retentive dosage forms, and transdermal patches. PharmaDax has received FDA approvals for generic versions of drugs such as glyburide, quetiapine fumarate ER, and metoprolol succinate ER, and offers co-development, marketing partnerships, dossier development, technology transfer, and contract development and manufacturing services. | Direttore/Membro del Consiglio | - |
Sandex Group Ltd. | Direttore/Membro del Consiglio | - |
Fortune Tower Group Corp. | Direttore/Membro del Consiglio | - |
Empax Pharma (Foshan) Inc. | Presidente | - |
Shengqun Pharmaceutical Co., Ltd. | Direttore/Membro del Consiglio | - |
Formazione di Hui Ju Chan
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
11
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
National Taipei University of Technology
 National Taipei University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Soochow University /Taiwan/
 Soochow University /Taiwan/ Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PharmaDax Inc.
 PharmaDax Inc. Pharmaceuticals: MajorHealth Technology Manufactures, develops and markets pharmaceutical products | Health Technology |
PharmaDax USA, Inc.
PharmaDax USA, Inc. Pharmaceuticals: MajorHealth Technology The company is located in the US. Part of PharmaDax Inc., PharmaDax USA, Inc. is an American pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty modified-release oral solid dosage drugs. The company focuses on complex sustained-release formulations primarily in central nervous system (CNS) and cardiovascular system (CVS) therapeutic areas. PharmaDax operates two GMP-compliant manufacturing facilities with a combined tablet production capacity of 600 million units annually, expandable to 1.5 billion, and employs around 230 team members across five countries. Its proprietary technology platforms include non-erosive adjustable drug delivery systems, modified-release orally disintegrating tablets, sustained-release gastro-retentive dosage forms, and transdermal patches. PharmaDax has received FDA approvals for generic versions of drugs such as glyburide, quetiapine fumarate ER, and metoprolol succinate ER, and offers co-development, marketing partnerships, dossier development, technology transfer, and contract development and manufacturing services. | Health Technology |
PharmaDax (Guangzhou), Inc. | |
Sandex Group Ltd. | |
Fortune Tower Group Corp. | |
Empax Pharma (Foshan) Inc. | |
Shengqun Pharmaceutical Co., Ltd. |
